<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0138-6557</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cub Med Mil]]></abbrev-journal-title>
<issn>0138-6557</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0138-65572022000200010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Asociación del uso de ivermectina en la mortalidad de pacientes con la COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Association of Ivermectin use on mortality in patients with COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mujica Alvarez]]></surname>
<given-names><![CDATA[Andrea Lucia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mejia]]></surname>
<given-names><![CDATA[Christian R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital San José del Callao  ]]></institution>
<addr-line><![CDATA[ Callao]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Sociedad Peruana de Medicina Interna  ]]></institution>
<addr-line><![CDATA[ Lima]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Continental  ]]></institution>
<addr-line><![CDATA[ Huancayo]]></addr-line>
<country>Perú</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>51</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0138-65572022000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0138-65572022000200010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0138-65572022000200010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La ivermectina ha sido utilizada para prevenir y tratar pacientes con la COVID-19, sin embargo, investigaciones han demostrado que su eficacia no justifica el uso.  Objetivo: Determinar la asociación del uso de ivermectina, mortalidad y otros 3 indicadores en pacientes con la COVID-19.  Métodos:  Estudio observacional de cohorte retrospectiva. Se revisaron las historias clínicas que estuvieron hospitalizados entre abril y octubre de 2020, quienes además del tratamiento estándar (oxigenoterapia, corticoide y enoxaparina), recibieron tratamiento con ivermectina por neumonía grave o crítica por la COVID-19. Se midieron 4 variables resultado: mortalidad, indicación de pase a la unidad de cuidados intensivos, días de hospitalización y tiempo de requerimiento de oxigenoterapia a alto flujo.  Resultados: El 42 % (126) de los pacientes falleció y el 52 % (159) tuvo indicación de pase a la unidad de cuidados intensivos. En el análisis multivariado, quienes tomaron una mayor dosis tuvieron mayor indicación de pase a cuidados intensivos (RRa: 1,10; IC 95 %: 1,01-1,20; valor p= 0,035), días de hospitalización (coeficiente: 5,07; IC 95 %: 2,15-11,92; valor p&lt; 0,001) y tiempo de requerimiento de oxigenoterapia con alto flujo (coeficiente: 3,33; IC 95 %: 1,56-7,09; valor p= 0,002).  Conclusión: Los pacientes que recibieron ivermectina tuvieron mayor probabilidad de indicación de pase a la unidad de cuidados intensivos, mayor tiempo de hospitalización y mayor tiempo de requerimiento de oxígeno a alto flujo, sin hallar relación con la mortalidad de los pacientes hospitalizados por la COVID-19. La administración de ivermectina antes o durante la hospitalización no tuvo beneficios.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Ivermectin has been used to prevent and treat COVID-19 patients, however, research has shown that its efficacy does not justify its use.  Objective:  To determine the association between the use of Ivermectin, mortality and 3 other indicators in patients with COVID-19.  Methods:  Observational retrospective cohort study. We reviewed the medical records of patients who were hospitalized between April and October 2020, who in addition to standard treatment (oxygen therapy, corticosteroid and enoxaparin), received treatment with Ivermectin for severe or critical COVID-19 pneumonia. Four outcome variables were measured: mortality, indication for transfer to the Intensive Care Unit days of hospitalization and time required for high-flow oxygen therapy.  Results:  Of patients, 42 % (126) died and 52 % (159) had indication for transfer to the Intensive Care Unit. In the multivariate analysis those who took a higher dose had a greater indication for transfer to Intensive Care Unit (RRa: 1.10; IC 95 %: 1.01-1.20; p-value= 0.035), days of hospitalization (coefficient: 5,07; IC 95 %: 2.15-11.92; p-value&lt; 0.001) and time requiring high-flow oxygen therapy (coefficient: 3.33; IC 95 %: 1.56-7.09; p-value= 0.002).  Conclusion:  Patients who received Ivermectin were more likely to be referred to the Intensive Care Unit, had a longer hospital stay, and required more time on high-flow oxygen, without finding a relationship with mortality in patients hospitalized for SARS-CoV-2. The administration of Ivermectin before or during hospitalization had no benefit.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ivermectina]]></kwd>
<kwd lng="es"><![CDATA[terapéutica]]></kwd>
<kwd lng="es"><![CDATA[infecciones por coronavirus]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2.]]></kwd>
<kwd lng="en"><![CDATA[ivermectin]]></kwd>
<kwd lng="en"><![CDATA[therapeutic]]></kwd>
<kwd lng="en"><![CDATA[coronavirus infections]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamed]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An overview on COVID-19: reality and expectation]]></article-title>
<source><![CDATA[Bulletin of the National Research Centre]]></source>
<year>2020</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-96</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dixit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yadav]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin: Potential role as repurposed drug for COVID-19]]></article-title>
<source><![CDATA[Malays J Med Sci]]></source>
<year>2020</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>154-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidary]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gharebaghi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen]]></article-title>
<source><![CDATA[The Journal of Antibiotics]]></source>
<year>2020</year>
<volume>73</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>593-602</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhimraj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Shumaker]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Lavergne]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baden]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[VC-C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infectious diseases society of america guidelines on the treatment and management of patients with Coronavirus Disease 2019 (COVID-19)]]></article-title>
<source><![CDATA[Clinical Infectious Diseases]]></source>
<year>2020</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paumgartten]]></surname>
<given-names><![CDATA[FJR]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[ACAX de]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues]]></article-title>
<source><![CDATA[Ciênc saúde coletiva]]></source>
<year>2020</year>
<volume>25</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3413-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action]]></article-title>
<source><![CDATA[Naunyn Schmiedebergs Arch Pharmacol]]></source>
<year>2020</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elkholy]]></surname>
<given-names><![CDATA[KO]]></given-names>
</name>
<name>
<surname><![CDATA[Hegazy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Erdinc]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Abowali]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin: A closer look at a potential remedy]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2020</year>
<volume>12</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>10378-85</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagstaff]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Sivakumaran]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Heaton]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Harrich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jans]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin is a specific inhibitor of importin &#945;/&#946;-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus]]></article-title>
<source><![CDATA[Biochemical Journal]]></source>
<year>2012</year>
<volume>443</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>851-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>Ministerio de Salud del Perú</collab>
<article-title xml:lang=""><![CDATA[Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectadas por COVID-19 en el Perú]]></article-title>
<source><![CDATA[Resolución Ministerial N° 193-2020-MINSA]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Lima ]]></publisher-loc>
<publisher-name><![CDATA[MINSA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saha Podder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chowdhury]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ibne Sina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wasin Mohosin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study]]></article-title>
<source><![CDATA[IMC Journal of Medical Science]]></source>
<year>2020</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto-Becerra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Culquichicón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado-Roca]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Araujo-Castillo]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world effectiveness of Hydroxychloroquine, Azithromycin, and Ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide healthcare system in Peru]]></article-title>
<source><![CDATA[MedRxiv]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camprubí]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Almuedo-Riera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martí-Soler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Subirà]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients]]></article-title>
<source><![CDATA[PLOS ONE]]></source>
<year>2020</year>
<volume>15</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spoorthi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sasank]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2]]></article-title>
<source><![CDATA[IAIM]]></source>
<year>2020</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>177-82</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>OMS</collab>
<source><![CDATA[La OMS interrumpe los grupos de tratamiento de la COVID-19 con hidroxicloroquina y con la combinación lopinavir/ritonavir]]></source>
<year>2020</year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohiuddin Chowdhury]]></surname>
<given-names><![CDATA[ATM]]></given-names>
</name>
<name>
<surname><![CDATA[Shahbaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Karim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients]]></article-title>
<source><![CDATA[EJMO]]></source>
<year>2021</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63-50</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgenstern]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Redondo]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[De León]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Canela]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tavares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020]]></article-title>
<source><![CDATA[MedRxiv]]></source>
<year>2020</year>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Murshed]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bhiuyan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Saber]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Robin]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline]]></article-title>
<source><![CDATA[Journal of Bangladesh College of Physicians and Surgeons]]></source>
<year>2020</year>
<numero>^s38</numero>
<issue>^s38</issue>
<supplement>38</supplement>
<page-range>10-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>PAHO</collab>
<source><![CDATA[Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews]]></source>
<year>2020</year>
<publisher-name><![CDATA[Pan American Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajter]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Fatteh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rajter]]></surname>
<given-names><![CDATA[J-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ICON (Ivermectin in COVID Nineteen) study: Use of Ivermectin is associated with lower mortality in hospitalized patients with COVID19]]></article-title>
<source><![CDATA[MedRxiv]]></source>
<year>2020</year>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niaee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gheibi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Namdar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Allami]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zolghadr]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Javadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial]]></article-title>
<source><![CDATA[Researsh Square]]></source>
<year>2020</year>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elgazzar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eltaweel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Youssef]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hany]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hafez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moussa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic]]></article-title>
<source><![CDATA[Researsh Square]]></source>
<year>2020</year>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kory]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Meduri]]></surname>
<given-names><![CDATA[GU]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Varon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berkowitz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kornfeld]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of the emerging evidence demonstrating the efficacy of Ivermectin in the prophylaxis and treatment of COVID-19]]></article-title>
<source><![CDATA[Frontiers in Public Health]]></source>
<year>2020</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
